Recent community engagement activities organized by experts at MRC/UVRI and LSHTM Uganda Research Unit have enabled the Unit to attain the recruitment target in its study. , an African-led HIV efficacy study, will provide critical information to move HIV vaccine information forward.
Behind the successes of the recruitment are Unit experts and community members ranging from scientists, community liaison specialists, community advisory board members, clinicians, community members, and professional support roles who contributed to the mobilization of 500 healthy male and female volunteers aged 18 to 39 from a pool of over 800 screened potential volunteers.
Follow-up of study volunteers will continue until the second quarter of 2024 and outcomes from the study will be valuable for informing future implementation and uptake strategies by local stakeholders and champions in settings where PrEP uptake is low even when accessible.
About PrEPVacc
The PrEPVacc study is coordinated by MRC/UVRI and LSHTM Uganda Research Unit under the leadership of our experts , Director of the Unit and Dr. Eugene Ruzagira, Trial Director. PrEPVacc鈥檚 will test whether a new form of oral PrEP, TAF/FTC (Descovy) taken daily, is equivalent or more effective than TDF/FTC (Truvada) taken daily, in the context of the current PrEP availability situation at . PrEPVacc鈥檚 vaccine study will test whether two experimental combination vaccine regimens can provide any protection against HIV in populations at risk of acquiring HIV. One regimen combines DNA with protein based vaccine, and the other combines DNA, MVA and protein based vaccine.
LSHTM's short courses provide opportunities to study specialised topics across a broad range of public and global health fields. From AMR to vaccines, travel medicine to clinical trials, and modelling to malaria, refresh your skills and join one of our short courses today.